At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 31 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Infliximab 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases
In Brief
A Phase 4 clinical trial evaluating Infliximab for Rheumatoid Arthritis and 3 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
CountriesUnited States
CollaboratorsCentocor, Inc.
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionJun 2010
Study CompletionAug 2010
TodayJul 2026
First PostedApr 18, 2007
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.2 years ago
Interventions
Infliximabdrug
Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.